Skip to Content

Crucell And Glaxo Will Combine Malaria vaccines

From Associated Press (April 6, 2010)

NEW YORK -- Drug makers Crucell NV and GlaxoSmithKline PLC said Tuesday they will work together on a new malaria vaccine composed of two drugs they were developing separately.

The companies had worked together to research a Crucell vaccine in preclinical studies, and want to begin testing their combined vaccine on humans. They said the preclinical research shows the drugs may work better together than they do separately.

Crucell said malaria kills about 900,000 people a year, making it one of the deadliest diseases in the world.

The experimental vaccine combines a GlaxoSmithKline vaccine called RTS,S/AS with a vaccine being developed by Crucell. GlaxoSmithKline is running late stage clinical tests of RTS,S/AS. Financial terms of the partnership were not disclosed.

The vaccine uses Crucell’s AdVac technology, which involves placing a section of genetic material from a virus or parasite into larger "vehicle" particle similar to the virus that causes the common cold. Crucell says that creates immunity to the disease, and works better against severe infectious diseases than older methods of vaccine creation.

Crucell of the Netherlands and London-based GlaxoSmithKline have been collaborating since late 2003 through a partnership with the Walter Reed Army Institute of Research.


Posted: April 2010